All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

ivosidenib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
isocitrate dehydrogenase inhibitors	5292	1448347-49-6

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: ivosidenib tibsovo AG-120

Ivosidenib is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. Susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate(2-HG) in the leukemia cells and where efficacy is predicted by 1) clinically meaningful remissions with the recommended dose of ivosidenib and/or 2) inhibition of mutant IDH1 enzymatic activity at concentrations of ivosidenib sustainable at the recommended dosage according to validated methods. The most common of such mutations are R132H and R132C substitutions. Molecular weight: 582.97 Formula: C28H22ClF3N6O3 CLOGP: 2.11 LIPINSKI: 2 HAC: 9 HDO: 1 TPSA: 119.29 ALOGS: -4.45 ROTB: 7 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
S (Water solubility)	0.04 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	GRK2,PDK1,PDK2,PDK4	4
pfas-class	PFAS structural alert (1 = True, 0 = False)	1

Approvals:

Date	Agency	Company	Orphan
July 20, 2018	FDA	AGIOS PHARMS INC
May 4, 2023	EMA	LES LABORATOIRES SERVIER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Differentiation syndrome	140.48	55.78	18	175	1313	90626941

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Differentiation syndrome	164.19	48.88	24	210	1789	42619312

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Differentiation syndrome	275.03	55.71	39	432	3005	110585823

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01XM02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Isocitrate dehydrogenase (IDH) inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
FDA MoA	N0000185506	Cytochrome P450 3A4 Inducers
FDA MoA	N0000185507	Cytochrome P450 2C9 Inducers
FDA EPC	N0000193987	Isocitrate Dehydrogenase 1 Inhibitor
FDA MoA	N0000193988	Isocitrate Dehydrogenase 1 Inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:145410	EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor

Related Drugs by ATC class:

L01XM Isocitrate dehydrogenase (IDH) inhibitors 3 drugs

enasidenibolutasidenibvorasidenib

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute myeloid leukemia, disease	indication	91861009
Biliary tract cancer	indication	312104005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.43	acidic
pKa2	0.21	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	10610125	June 21, 2030	A METHOD FOR TREATING NEWLY DIAGNOSED AML WITH IVOSIDENIB AND AZACITIDINE WHEREIN THE AML HAS AN IDH1 MUTATION CAPABLE OF CONVERTING ALPHA-KETOGLUTARATE TO 2-HYDROXYGLUTARATE (2HG)
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	10610125	June 21, 2030	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	10610125	June 21, 2030	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	10717764	Jan. 18, 2033	A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY AN IDH1 MUTATION
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	11667673	Jan. 18, 2033	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9850277	Jan. 18, 2033	A METHOD FOR TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WITH IVOSIDENIB IN COMBINATION WITH AZACITIDINE WHEREIN THE CANCER IS NEWLY DIAGNOSED AML
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9850277	Jan. 18, 2033	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9850277	Jan. 18, 2033	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9850277	Jan. 18, 2033	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML)
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9850277	Jan. 18, 2033	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9850277	Jan. 18, 2033	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9474779	Aug. 19, 2033	A METHOD FOR TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WITH IVOSIDENIB IN COMBINATION WITH AZACITIDINE WHEREIN THE CANCER IS NEWLY DIAGNOSED AML
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9474779	Aug. 19, 2033	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9474779	Aug. 19, 2033	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9474779	Aug. 19, 2033	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML)
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9474779	Aug. 19, 2033	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9474779	Aug. 19, 2033	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	10799490	March 13, 2035	A METHOD FOR TREATING AML BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING IVOSIDENIB WHEREIN THE AML IS NEWLY DIAGNOSED AND CHARACTERIZED BY A MUTANT IDH1 AND THE COMPOSITION IS ADMINISTERED IN COMBINATION WITH AZACITIDINE
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	10799490	March 13, 2035	A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND THE AML IS NEWLY DIAGNOSED
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	10799490	March 13, 2035	A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND WHERE THE AML IS RELAPSED/REFRACTORY
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9968595	March 13, 2035	A METHOD FOR TREATING AML BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING IVOSIDENIB WHEREIN THE AML IS NEWLY DIAGNOSED AND CHARACTERIZED BY A MUTANT IDH1 AND THE COMPOSITION IS ADMINISTERED IN COMBINATION WITH AZACITIDINE
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9968595	March 13, 2035	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9968595	March 13, 2035	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	9968595	March 13, 2035	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	10653710	Oct. 18, 2036	A METHOD FOR TREATING NEWLY DIAGNOSED AML CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 SELECTED FROM R132H, R132C, R132L, R132V, R132S AND R132GF BY ADMINISTERING IVOSIDENIB AND AZACITIDINE
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	10980788	June 7, 2039	A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	10980788	June 7, 2039	A METHOD OF TREATING RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	10980788	June 7, 2039	TREATING NEWLY DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	10980788	June 7, 2039	TREATING NEWLY DIAGNOSED AML CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE OF IVOSIDENIB TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL, IN COMBINATION WITH AZACITIDINE
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	10980788	June 7, 2039	TREATING RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	May 2, 2026	TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST IN ADULT PTS WHO ARE >=75 YRS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	Oct. 24, 2026	FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES (MDS) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	Aug. 25, 2028	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
250MG	TIBSOVO	SERVIER	N211192	July 20, 2018	RX	TABLET	ORAL	Oct. 24, 2030	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES (MDS) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Isocitrate dehydrogenase [NADP] cytoplasmic	Enzyme	O75874	IDHC_HUMAN	INHIBITOR	IC50	7.15		SCIENTIFIC LITERATURE	DRUG LABEL
Isocitrate dehydrogenase [NADP], mitochondrial	Enzyme	P48735	IDHP_HUMAN		IC50	5.14		CHEMBL

External reference:

ID	Source
Q2PCN8MAM6	UNII
4037715	VANDF
C4682397	UMLSCUI
CHEBI:145430	CHEBI
IV3	PDB_CHEM_ID
CHEMBL3989958	ChEMBL_ID
71657455	PUBCHEM_CID
DB14568	DRUGBANK_ID
D11090	KEGG_DRUG
10225	INN_ID
C000627630	MESH_SUPPLEMENTAL_RECORD_UI
9217	IUPHAR_LIGAND_ID
773137008	SNOMEDCT_US
773232006	SNOMEDCT_US
285271	MMSL
34590	MMSL
d08845	MMSL
017647	NDDF
2049873	RXNORM

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TIBSOVO	HUMAN PRESCRIPTION DRUG LABEL	1	72694-617	TABLET, FILM COATED	250 mg	ORAL	NDA	31 sections